证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-097 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 中国 NMPA 注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 关于子公司冠状动脉刻痕球囊扩张导管获得 近日，蓝帆医疗股份有限公司（以下简称"公司"）接到通知，公司心脑血管事业 部子公司山东吉威医疗制品有限公司自主研发和生产的三类医疗器械产品"冠状动脉 刻痕球囊扩张导管"（以下简称"星痕™"）通过国家药品监督管理局（NMPA）的审查， 正式获得中华人民共和国医疗器械注册证。现将相关情况公告如下： 一、获批产品基本信息 产品名称：冠状动脉刻痕球囊扩张导管 注册人名称：山东吉威医疗制品有限公司 注册证编号：国械注准20253032515 星痕™冠状动脉刻痕球囊扩张导管的成功获批，不仅为临床处理复杂冠状动脉病 1 变提供了又一精准高效的预扩张选择，也标志着蓝帆医疗心脑血管事业部在构建"PCI 优化全链路解决方案"的战略拼图更加完整，在 PCI 治疗中进一步成功实现从简单到 复杂病变整体解决方案的"一站式"供应，预期将对 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-096 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于子公司为公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 限公司与浙商银行股份有限公司济南分行签订了《最高额抵押合同》，山东蓝帆新材料 有限公司为公司向浙商银行股份有限公司济南分行申请授信提供不动产抵押担保。 本次担保金额全部发生后未超过公司第六届董事会第十六次会议、2024年第三次 临时股东大会审议通过的2025年度公司及子公司申请授信及担保额度的金额范围，无 需另行召开董事会或股东会审议。 截至本公告发布之日，公司在2024年第三次临时股东大会批准范围内担保额度及 使用情况如下： 单位：万元人民币 | 新增担 | 是 | 被担保 | 本次担保 | 保额度 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002382 证券简称：蓝帆医疗 公告编号：2025-095 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 本次担保金额全部发生后未超过公司第六届董事会第十六次会议、2024年第三次临时股东大会审议通过 的2025年度公司及子公司申请授信及担保额度的金额范围，无需另行召开董事会或股东会审议。 关于公司为子公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事会第十六次会议、2024 年12月23日召开了2024年第三次临时股东大会，审议并通过了《关于2025年度公司及子公司申请授信及 担保额度预计的议案》，公司及子公司2025年度拟向银行等金融机构申请综合授信总额不超过人民币 17.10亿元，授信品种包括但不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融 资租赁等综合授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子公 ...

证券日报网讯 12月5日晚间，蓝帆医疗发布公告称，近日公司为全资子公司山东蓝帆新材料有限公司向 兴业银行淄博分行申请8，750万元流动资金借款提供连带责任担保，本次担保后山东新材料担保余额升 至30，246万元，剩余可用担保额度82，789.77万元；截至公告日，公司及子公司担保最高额334， 114.31万元，占2024年度经审计净资产40.81%，无逾期担保。 （文章来源：证券日报） ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2025-095 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司为子公司向银行申请授信提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2024年12月6日召开了第六届董事 会第十六次会议、2024年12月23日召开了2024年第三次临时股东大会，审议并通过了 《关于2025年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2025 年度拟向银行等金融机构申请综合授信总额不超过人民币17.10亿元，授信品种包括但 不限于流动资金贷款、保函、银行承兑汇票、国内信用证、国内保理、融资租赁等综 合授信业务（具体业务品种以相关金融机构审批为准），具体融资金额将视公司及子 公司生产运营对资金的需求来确定。公司及子公司将根据金融机构的授信要求为上述 综合授信提供担保额度总计不超过人民币17.10亿元，其中，预计为公司及资产负债率 70 ...

证券之星消息，截至2025年12月4日收盘，蓝帆医疗(002382)报收于5.46元，下跌2.5%，换手率0.86%， 成交量8.56万手，成交额4706.56万元。 12月4日的资金流向数据方面，主力资金净流出603.74万元，占总成交额12.83%，游资资金净流入 210.88万元，占总成交额4.48%，散户资金净流入392.86万元，占总成交额8.35%。 近5日资金流向一览见下表： | 指标 | 蓝帆医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 54.99亿元 | 109.58亿元 | 63 124 | | 净资产 | 97.07亿元 | 38.93亿元 | 7 124 | | 净利润 | -2.86亿元 | 2.12亿元 | 124 124 | | 市盈率(动) | -14.42 | 60.57 | - 124 | | 市净率 | 0.71 | 3.81 | 1 124 | | 毛利率 | 13.66% | 51.22% | 121 124 | | 净利率 | -7.24% | 9.57% | 109 124 | | ROE | - ...

证券之星消息，截至2025年12月3日收盘，蓝帆医疗(002382)报收于5.6元，下跌0.71%，换手率0.69%， 成交量6.93万手，成交额3897.2万元。 12月3日的资金流向数据方面，主力资金净流出318.14万元，占总成交额8.16%，游资资金净流出209.39 万元，占总成交额5.37%，散户资金净流入527.53万元，占总成交额13.54%。 近5日资金流向一览见下表： | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-03 | 5.60 -0.71% | -318.14万 | -8.16% | -209.39万 | -5.37% | 527.53万 | - 13.54% | | 2025-12-02 | 5.64 -0.88% | -1293.93万 | -32.24% | 447.35万 | 11.15% | 846.58万 | 21.09% | | 2025-12-01 | 5.69 -0.70% | ...

Group 1 - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors [4] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [4] - Yongtai Energy's actual controller Wang Guangxi received a notice of investigation from the China Securities Regulatory Commission for matters unrelated to the company [4] Group 2 - Shenzhou Pharmaceutical's controlling shareholder plans to reduce its stake by no more than 3% [4] - Zhenhua Group intends to increase its stake in China Jushi by 550 million to 1.1 billion yuan [4] - Jihong Co., Ltd. and its concerted parties plan to reduce their stake by no more than 2.93% [4] Group 3 - XJ Electric won a 1.518 billion yuan procurement project from the State Grid [4] - China XD Electric's subsidiaries collectively won procurement projects from the State Grid worth approximately 2.98 billion yuan [4] - Chaozhuo Aerospace's actual controller will change to the Hubei Provincial State-owned Assets Supervision and Administration Commission, with stock resuming trading on December 1 [4] Group 4 - Huakong Saige terminated its specific object stock issuance [5] - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding 20 billion yuan [5] Group 5 - Blue Sail Medical's board proposed to lower the conversion price of "Blue Sail Convertible Bonds" [6] - ST Lifang's stock will be subject to delisting risk warning and will be suspended from trading on December 1 [7] - Cambrian elected Chen Tianshi as chairman [8]

Key Points - Guizhou Moutai elected Chen Hua as the chairman of the fourth board of directors and plans to repurchase shares between RMB 1.5 billion and RMB 3 billion [1] - Tianfeng Securities is under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure and illegal financing [1] Share Buybacks - Demai Technology raised the upper limit for share repurchase to RMB 45 per share [5] - Jianbang Technology plans to repurchase shares worth between RMB 15 million and RMB 30 million [5] - Huayuan Holdings intends to repurchase shares worth between RMB 30 million and RMB 60 million [5] Major Investments - Jinling Pharmaceutical plans to invest RMB 893 million in hospital expansion projects [7] - Dongfang Mingzhu intends to invest approximately RMB 500 million to establish a partnership and acquire part of the equity of New H3C [7] - Chang'an Automobile aims to establish a robotics company to develop innovative products and solutions [7] Mergers and Acquisitions - Kaizhong Co. plans to acquire 60% of Anhui Tuosheng's equity, with stock resuming trading on December 1 [7] - Youa Co. has resumed the review process for issuing shares and cash to purchase assets [7] - Jiasheng Technology intends to acquire controlling interest in Shudun Information Technology Co., with stock continuing to be suspended [7] Financing Activities - Shenzhen Energy plans to apply for a public bond issuance with a total scale not exceeding RMB 20 billion [7] - Huakong Saige has terminated its specific object stock issuance [7]

Core Viewpoint - Bluefan Medical (002382) has shown a decline in stock price and financial performance, with significant net losses reported in recent quarters, indicating potential challenges in the medical device industry [1][3]. Financial Performance - As of November 28, 2025, Bluefan Medical's stock closed at 5.73 yuan, down 0.35%, with a trading volume of 76,600 hands and a transaction value of 43.58 million yuan [1]. - In the third quarter of 2025, the company reported a main revenue of 14.01 billion yuan, a year-on-year decrease of 15.02%, and a net profit attributable to shareholders of -1.51 billion yuan, a decline of 153.64% [3]. - For the first three quarters of 2025, the company's main revenue was 41.82 billion yuan, down 10.15%, with a net profit of -2.86 billion yuan, a decrease of 30.09% [3]. Market Position - Bluefan Medical's total market value is 5.771 billion yuan, significantly lower than the industry average of 11.144 billion yuan, ranking 62 out of 124 in the medical device sector [3]. - The company's net asset stands at 9.707 billion yuan, ranking 7 in the industry, while its net profit is the lowest in the sector at -2.86 billion yuan, ranking 124 [3]. - The company's price-to-earnings ratio is -15.14, and its price-to-book ratio is 0.75, indicating a low valuation compared to the industry average [3]. Capital Flow - On November 28, 2025, the net inflow of main funds was 711,400 yuan, accounting for 1.63% of the total transaction value, while retail investors saw a net outflow of 2.1339 million yuan, representing 4.9% of the total [1][2]. - Over the past five days, the stock has experienced fluctuating capital flows, with significant net outflows from retail investors on multiple days [2].